ARK Investment Management LLC Acquires 146,141 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

ARK Investment Management LLC boosted its holdings in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 7.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,047,687 shares of the biotechnology company’s stock after buying an additional 146,141 shares during the quarter. ARK Investment Management LLC owned approximately 7.66% of Arcturus Therapeutics worth $64,564,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. New York State Teachers Retirement System bought a new position in shares of Arcturus Therapeutics in the third quarter worth approximately $53,000. Great West Life Assurance Co. Can lifted its holdings in shares of Arcturus Therapeutics by 29.9% in the first quarter. Great West Life Assurance Co. Can now owns 2,679 shares of the biotechnology company’s stock worth $64,000 after buying an additional 616 shares in the last quarter. BNP Paribas Arbitrage SA lifted its holdings in shares of Arcturus Therapeutics by 63.4% in the second quarter. BNP Paribas Arbitrage SA now owns 5,043 shares of the biotechnology company’s stock worth $79,000 after buying an additional 1,956 shares in the last quarter. Point72 Middle East FZE purchased a new position in shares of Arcturus Therapeutics in the fourth quarter worth $79,000. Finally, Point72 Hong Kong Ltd lifted its holdings in shares of Arcturus Therapeutics by 3,653.2% in the second quarter. Point72 Hong Kong Ltd now owns 6,493 shares of the biotechnology company’s stock worth $102,000 after buying an additional 6,320 shares in the last quarter. 94.54% of the stock is currently owned by institutional investors.

Arcturus Therapeutics Trading Up 2.3 %

Shares of ARCT opened at $32.86 on Thursday. The company’s fifty day simple moving average is $36.16 and its 200-day simple moving average is $29.36. The company has a market cap of $884.59 million, a P/E ratio of -31.60 and a beta of 2.64. Arcturus Therapeutics Holdings Inc. has a twelve month low of $15.32 and a twelve month high of $43.81.

Insider Transactions at Arcturus Therapeutics

In other news, COO Pad Chivukula sold 17,435 shares of the company’s stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $35.02, for a total value of $610,573.70. Following the transaction, the chief operating officer now directly owns 473,448 shares in the company, valued at $16,580,148.96. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 13.80% of the company’s stock.

Wall Street Analyst Weigh In

ARCT has been the topic of a number of recent research reports. Citigroup upped their price target on shares of Arcturus Therapeutics from $40.00 to $48.00 and gave the company a “buy” rating in a research note on Thursday, February 8th. Canaccord Genuity Group initiated coverage on shares of Arcturus Therapeutics in a research note on Wednesday, December 13th. They set a “buy” rating and a $90.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price target on shares of Arcturus Therapeutics in a research note on Wednesday, March 20th. William Blair reaffirmed an “outperform” rating on shares of Arcturus Therapeutics in a research note on Friday, March 8th. Finally, Canaccord Genuity Group initiated coverage on shares of Arcturus Therapeutics in a research note on Wednesday, December 13th. They set a “buy” rating on the stock. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, Arcturus Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $57.71.

Arcturus Therapeutics Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.